pC1INH

pC1INH refers to the recombinant form of human plasma kallikrein inhibitor, also known as C1 inhibitor (C1-INH). C1-INH is a protein that plays a crucial role in regulating the complement system and the contact activation system. It is a serine protease inhibitor, meaning it inactivates enzymes that have a serine residue in their active site. In the context of hereditary angioedema (HAE), a condition characterized by recurrent episodes of swelling, dysfunctional or deficient C1-INH is the underlying cause. Recombinant C1-INH, often abbreviated as rC1-INH or pC1INH, is a therapeutic agent developed to treat these attacks. It is produced using recombinant DNA technology. By providing a functional C1-INH protein, recombinant therapy aims to restore the normal regulation of inflammatory pathways, thereby preventing or reducing the severity of angioedema attacks. This therapy can be administered intravenously. The development of pC1INH represents a significant advancement in the management of HAE, offering an effective treatment option for individuals suffering from this rare genetic disorder.